Background: Accurate risk assessment for carcinogens requires understanding how genetic variation modulates exposure. Following discovery of new polymorphic genes in environmental response pathways, it is necessary to characterize their impact on function (genotype/phenotype relationship).
Aims : 1) Characterize functional role of promoter and coding region polymorphisms of metabolism genes using standard biochemical, molecular and cellular bioassay techniques (e.g. CYPs, GSTs, PGEs). 2) Develop model approaches for characterizing functional effects of polymorphisms in transcription factors, transcription factor binding sites, and other regulatory sequence elements using expression profiling. This project focuses on the functional characterization of variation in environmental response genes. Accomplishments: 1. Expression-based discovery of variation in the human glutathione S-transferase M3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation. Discovery and functional evaluation of biologically significant regulatory polymorphisms (rSNPs) in carcinogen metabolism genes is a difficult challenge because the phenotypic consequences may be both transient and subtle. We have used a gene expression screening approach to identify a functional rSNP in glutathione S-transferase M3 (GSTM3). Antilla et al. (1) proposed that variation in GSTM3 expression was affected by exposure to cigarette smoke and inheritance of the GSTM1 null genotype. To investigate the mechanism of GSTM3 expression variation, we measured GSTM3 expression in lymphoblast cells from a human CEPH family and observed a low expression phenotype. Promoter sequencing revealed two novel GSTM3 promoter SNPs: an A/C and A/G SNP, 63-bp and 783-bp upstream of the codon 1 start site, respectively. In this pedigree, the two children homozygous for the -63C/C genotype had eight-fold lower GSTM3 expression relative to the two children with the -63A/A genotype, with no association between the A-783G SNP and GSTM3 expression. Further evaluation using genotyped glioma cell lines and with luciferase reporter constructs showed the -63C allele was associated with lower GSTM3 expression (p < 0.0001; p < 0.003). RNA polymerase II chromatin immunoprecipitation3 (ChIP) was combined with quantitative probed-based allelic-discrimination genotyping to provide direct evidence of a nine-fold reduced RNA polymerase II binding capacity for the -63C allele. These results demonstrate that the GSTM3 -63C allele strongly affects gene expression in human cell lines and suggests that individuals who carry the low expression allele may be deficient in glutathione transferase catalyzed biological functions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES090604-09
Application #
7170017
Study Section
(LCBR)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2005
Total Cost
Indirect Cost
Name
U.S. National Inst of Environ Hlth Scis
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Liu, Xuemei; Campbell, Michelle R; Pittman, Gary S et al. (2005) Expression-based discovery of variation in the human glutathione S-transferase M3 promoter and functional analysis in a glioma cell line using allele-specific chromatin immunoprecipitation. Cancer Res 65:99-104
Wang, Xuting; Tomso, Daniel J; Liu, Xuemei et al. (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84-90
Lee, Su-Jun; Bell, Douglas A; Coulter, Sherry J et al. (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-9
Grant, Delores J; Hall, Ingrid J; Eastmond, David A et al. (2004) Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood. Mutat Res 560:1-10
Mammen, Jennifer S; Pittman, Gary S; Li, Ying et al. (2003) Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 24:1247-55
Fritsche, E; Baek, S J; King, L M et al. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468-76
Grant, D J; Bell, D A (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? Mol Carcinog 29:198-204